<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111485</url>
  </required_header>
  <id_info>
    <org_study_id>MP-37-2017-2573</org_study_id>
    <nct_id>NCT03111485</nct_id>
  </id_info>
  <brief_title>Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease</brief_title>
  <official_title>Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weston Brain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will assess whether long-acting levodopa taken at night improves obstructive sleep
      apnea (OSA) in patients with Parkinson's disease (PD), as compared with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with Parkinson's disease and sleep apnea will take long-acting levodopa and
      placebo at bedtime for 2 weeks each, in a randomized order, with a 2-week washout period
      in-between. Sleep studies will be done at the end of each period. The primary outcome will be
      the apnea-hypopnea index change from baseline to on-medication, comparing active medication
      to placebo. Other outcomes will include other polysomnographic parameters such as oxygenation
      measures and sleep architecture variables, as well as the Epworth Sleepiness Scale, the
      Montreal Cognitive Assessment, the Parkinson's disease sleep scale and the Unified
      Parkinson's Disease Rating Scale. Adverse events will be closely monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea-hypopnea index (AHI)</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients having adverse events leading to discontinuation of drug (Feasibility and tolerability)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Proportion of patients having adverse events leading to discontinuation of drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>oxygen desaturation index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>mean oxygen saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>time with saturation below 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sleep quality from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>Sleep efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sleep quality from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>total sleep time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sleep quality from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>wake after sleep onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sleep quality from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>sleep stages distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective sleep quality from polysomnography</measure>
    <time_frame>2 weeks</time_frame>
    <description>arousal index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective sleep quality</measure>
    <time_frame>2 weeks</time_frame>
    <description>Parkinson's Disease Sleep Scale-R</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness</measure>
    <time_frame>2 weeks</time_frame>
    <description>Epworth Sleepiness Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-motor symptoms</measure>
    <time_frame>2 weeks</time_frame>
    <description>MDS-UPDRS part I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>2 weeks</time_frame>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>A (drug-placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (placebo-drug)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet CR</intervention_name>
    <description>Capsule 250 mg / 50 mg taken at bedtime</description>
    <arm_group_label>A (drug-placebo)</arm_group_label>
    <arm_group_label>B (placebo-drug)</arm_group_label>
    <other_name>Long acting levodopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Capsule taken at bedtime</description>
    <arm_group_label>A (drug-placebo)</arm_group_label>
    <arm_group_label>B (placebo-drug)</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of idiopathic PD consistent with the UK Brain Bank;

          2. Presence of OSA on screening PSG, as defined by an AHI â‰¥ 15/h (moderate to severe
             OSA);

          3. Stable regimen of anti-PD medication for 4 weeks prior to entry into the study, and no
             planned change during the study

        Exclusion Criteria:

          1. Other major neurological disorder;

          2. Already taking long-acting levodopa (at any time of day);

          3. Taking short-acting levodopa at bedtime or during the night;

          4. Any contraindication to long-acting levodopa (see below);

          5. Severe levodopa induced dyskinesias;

          6. Already on or requiring treatment for restless legs syndrome ;

          7. Body mass index &gt;35 kg/m2;

          8. Intercurrent upper respiratory tract infection;

          9. Other known cause of OSA (e.g. craniofacial malformation);

         10. Active treatment of OSA (CPAP, dental appliance or other), unless willing to stop
             treatment 2 weeks prior to start and during the duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Kaminska</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Robinson</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>36479</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Robinson</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>36479</phone_ext>
      <email>ann.robinson@mail.mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Marta Kaminska</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

